{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06271252",
            "orgStudyIdInfo": {
                "id": "OriCAR-017 US-P1"
            },
            "organization": {
                "fullName": "OriCell Therapeutics Co., Ltd.",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study",
            "officialTitle": "A Phase I/II, Open-label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Anti-GPRC5D CAR-T Cell Product (OriCAR-017) in Subjects With Relapsed/Refractory Multiple Myeloma.",
            "therapeuticArea": [
                "Oncology and Hematology",
                "Other",
                "Immunology and Rheumatology"
            ],
            "study": "a-study-to-evaluate-the-safety-pk-pd-of-oricar-in-subjects-with-rr-mm-rigel-study"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-05",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-04-03",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-12-12",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2028-04-12",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-01-26",
            "studyFirstSubmitQcDate": "2024-02-14",
            "studyFirstPostDateStruct": {
                "date": "2024-02-21",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-05-06",
            "lastUpdatePostDateStruct": {
                "date": "2024-05-08",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "OriCell Therapeutics Co., Ltd.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The is a first clinical study for Oricell Therapeutics Inc. in the United States to evaluate the safety, PK, PD and preliminary efficacy of our anti-GPRC5D cell product (OriCAR-017) in subjects with relapsed/refractory multiple myeloma.\n\nRIGEL Study",
            "detailedDescription": "This is a Phase I/II, open-label multicenter study to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of anti-GPRC5D CAR-T cell product (OriCAR-017) in subjects with relapsed/refractory multiple myeloma\". The study will consist of a Phase I dose escalation stage involving three doses as a single IV infusion) with up to 18 evaluable subjects and a dose expansion stage with 10-15 evaluable subjects, followed by a Phase II stage with up to 48 evaluable subjects."
        },
        "conditionsModule": {
            "conditions": [
                "Neoplasms, Plasma Cell",
                "Neoplasms by Histologic Type",
                "Neoplasms",
                "Hemostatic Disorders",
                "Vascular Diseases",
                "Cardiovascular Diseases",
                "Paraproteinemias",
                "Blood Protein Disorders",
                "Hematologic Diseases",
                "Hemorrhagic Disorders",
                "Lymphoproliferative Disorders",
                "Immunoproliferative Disorders",
                "Immune System Diseases",
                "Multiple Myeloma"
            ],
            "keywords": [
                "R/R MM, CAR-T"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 81,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "OriCAR-017",
                    "type": "EXPERIMENTAL",
                    "description": "Single OriCAR-017 infusion",
                    "interventionNames": [
                        "Drug: OriCAR-017"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "OriCAR-017",
                    "description": "Anti-GPRC5D CAR-T cell product",
                    "armGroupLabels": [
                        "OriCAR-017"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Maximum tolerated dose (MTD) of OriCAR-017 US-P1",
                    "description": "The MTD is defined as the highest dose with an observed incidence of DLT in no more than one out of six patients treated at a particular dose level.",
                    "timeFrame": "Up to 28 days"
                },
                {
                    "measure": "Dose-limiting toxicity (DLT)",
                    "description": "A DLT is defined as any of the treatment-emergent adverse events (TEAEs; a TEAE is defined as an adverse event \\[AE\\] that starts on or after the first administration of study medication) condition or concomitant medications.",
                    "timeFrame": "Up to 28 days"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Evaluate PK parameters of OriCAR-017 in subjects with relapsed/refractory MM",
                    "description": "Assess concentration of CAR-T cells in peripheral blood",
                    "timeFrame": "Up to 2 years"
                },
                {
                    "measure": "Evaluate PD parameters of OriCAR-017 in subjects with relapsed/refractory MM",
                    "description": "Assess PD markers related to CAR-T therapy in peripheral blood.",
                    "timeFrame": "Up to 2 years"
                },
                {
                    "measure": "Assessment of Duration of Response (DOR) of treatment in patients with RR/MM",
                    "description": "DOR as assessed by Local Investigators according to the IMWG Criteria",
                    "timeFrame": "Up to 2 years"
                },
                {
                    "measure": "Progress-Free Survival (PFS) of treatment in patients with RR/MM",
                    "description": "PFS as assessed by Local Investigators according to the IMWG Criteria",
                    "timeFrame": "Up to 2 years"
                },
                {
                    "measure": "Assessment of Overall Survival (OS) of treatment in patients with RR/MM",
                    "description": "OS as assessed by Local Investigators according to the IMWG Criteria",
                    "timeFrame": "Up to 2 years"
                },
                {
                    "measure": "Assessment of MRD negative Rate",
                    "description": "Proportion of subjects with MRD negative status by flow cytometry",
                    "timeFrame": "Up to 2 years"
                },
                {
                    "measure": "Assessment of Overall Response Rate (ORR)",
                    "description": "Percentage of subjects with PR, + VGPR+ CR + strict complete response (sCR) as assessed by Local Investigator according to the IMWG criteria",
                    "timeFrame": "Up to 2 years"
                },
                {
                    "measure": "Assessment of Disease Control Rate (DCR)",
                    "description": "Percentage of subjects with CBR (Clinical Benefit Rate) + Stable Disease as assessed by Local Investigator according to IMWG Criteria",
                    "timeFrame": "Up to 2 years"
                },
                {
                    "measure": "Assessment of Clinical Benefit Rate (CBR)",
                    "description": "Percentage of subjects with ORR + Minimal Response by Local Investigator according to IMWG Criteria",
                    "timeFrame": "Up to 2 years"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\nCapable of giving signed informed consent\n\nSubjects aged 18 to 75 years (inclusive) at Screening (signing the ICF).\n\nExpected survival period is \\>12 weeks.\n\nDiagnosis of MM according to the IMWG criteria (2016 version).\n\nOne of the following criteria must be met:\n\nIf immunoglobulin (Ig)G type MM, then serum M protein \\>10 g/L; if IgA, IgD, IgE or IgM type MM, then serum M protein \\>5 g/L\n\nUrine M protein level \\>200 mg/24 hour\n\nIf light chain type MM, then serum free light chain (sFLC) \\>100 mg/L and K/\u03bb FLC ratio is abnormal.\n\nExtramedullary lesions (\\>1 cm for diameter of the short axis).\n\nFor Phase I (dose-escalation) - Subjects who had received at least 3 prior lines of therapy, had previous exposure to BCMA-Ag+ therapies, and were refractory to the last line of therapy.\n\nFor Phase I (dose-expansion) and Phase II: Subjects with previous exposure to BCMA directed therapies including BCMA bispecific antibody (e.g., teclistamab), BCMA antibody directed conjugate (such as BLENREP), and BCMA-CAR-T (such as CARVYKT1TM)\n\nSubjects with adequate hematologic, renal, hepatic, pulmonary and cardiac function.\n\nSubject and partners willing to take and or use effective contraceptive measures until 2 years post IMP infusion.\n\nExclusion Criteria:\n\nPregnant or breastfeeding.\n\nSeropositive for history of human immunodeficiency virus Active Hepatitis B infection and or Hepatitis C infection\n\nKnown active or prior history of CNS involvement\n\nHistory of autoimmune diseases (such as Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus) caused damage to terminal organs or required systemic application of immunosuppressive or other drugs in the past 2 years\n\nPresence of uncontrolled active infection\n\nSubjects who received autologous hematopoietic stem cell transplantation (ASCT) within 8 weeks of Screening Visit or who plan to undergo ASCT during the study.\n\nSubjects who received allogeneic stem cell therapy.\n\nAny condition that in the opinion of the Investigator, would interfere with evaluation of the IMP.\n\nReceived Bendamustine treatment 1 year prior to Screening Visit.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "75 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "locations": [
                {
                    "facility": "Northside Hospital",
                    "status": "RECRUITING",
                    "city": "Atlanta",
                    "state": "Georgia",
                    "zip": "30342",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Melhem Solh",
                            "role": "CONTACT",
                            "phone": "404-255-1930",
                            "email": "msolh@bmtga.com"
                        },
                        {
                            "name": "Caitlin Guzowski",
                            "role": "CONTACT",
                            "phone": "4042551930",
                            "email": "caitlin.guzowski@northside.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.749,
                        "lon": -84.38798
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000009101",
                    "term": "Multiple Myeloma"
                },
                {
                    "id": "D000054219",
                    "term": "Neoplasms, Plasma Cell"
                },
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000002318",
                    "term": "Cardiovascular Diseases"
                },
                {
                    "id": "D000014652",
                    "term": "Vascular Diseases"
                },
                {
                    "id": "D000020141",
                    "term": "Hemostatic Disorders"
                },
                {
                    "id": "D000008232",
                    "term": "Lymphoproliferative Disorders"
                },
                {
                    "id": "D000006402",
                    "term": "Hematologic Diseases"
                },
                {
                    "id": "D000006474",
                    "term": "Hemorrhagic Disorders"
                },
                {
                    "id": "D000001778",
                    "term": "Blood Coagulation Disorders"
                },
                {
                    "id": "D000010265",
                    "term": "Paraproteinemias"
                },
                {
                    "id": "D000001796",
                    "term": "Blood Protein Disorders"
                },
                {
                    "id": "D000007154",
                    "term": "Immune System Diseases"
                },
                {
                    "id": "D000007160",
                    "term": "Immunoproliferative Disorders"
                }
            ],
            "ancestors": [
                {
                    "id": "D000008206",
                    "term": "Lymphatic Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M12058",
                    "name": "Multiple Myeloma",
                    "asFound": "Multiple Myeloma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M27588",
                    "name": "Neoplasms, Plasma Cell",
                    "asFound": "Neoplasms, Plasma Cell",
                    "relevance": "HIGH"
                },
                {
                    "id": "M17400",
                    "name": "Vascular Diseases",
                    "asFound": "Vascular Disease",
                    "relevance": "HIGH"
                },
                {
                    "id": "M21977",
                    "name": "Hemostatic Disorders",
                    "asFound": "Hemostatic Disorder",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5059",
                    "name": "Blood Coagulation Disorders",
                    "asFound": "Hemostatic Disorder",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11225",
                    "name": "Lymphoproliferative Disorders",
                    "asFound": "Lymphoproliferative Disorders",
                    "relevance": "HIGH"
                },
                {
                    "id": "M9490",
                    "name": "Hematologic Diseases",
                    "asFound": "Hematologic Diseases",
                    "relevance": "HIGH"
                },
                {
                    "id": "M13178",
                    "name": "Paraproteinemias",
                    "asFound": "Paraproteinemias",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10200",
                    "name": "Immune System Diseases",
                    "asFound": "Immune System Diseases",
                    "relevance": "HIGH"
                },
                {
                    "id": "M9560",
                    "name": "Hemorrhagic Disorders",
                    "asFound": "Hemorrhagic Disorders",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "asFound": "Neoplasms by Histologic Type",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5077",
                    "name": "Blood Protein Disorders",
                    "asFound": "Blood Protein Disorders",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10206",
                    "name": "Immunoproliferative Disorders",
                    "asFound": "Immunoproliferative Disorders",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11203",
                    "name": "Lymphatic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T3947",
                    "name": "Multiple Myeloma",
                    "asFound": "Multiple Myeloma",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC14",
                    "name": "Heart and Blood Diseases"
                },
                {
                    "abbrev": "BC15",
                    "name": "Blood and Lymph Conditions"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        }
    },
    "hasResults": false
}